The new 2014 non-GAAP EPS guidance represents 9-14% growth vs 2013.
Note: The non-GAAP 2014 EPS guidance includes contribution from the developed-markets branded-generics business sold to MYL (#msg-104271033 because this deal will not close until early 2015. (Starting in 3Q14, the business sold to MYL will be accounted for as a discontinued operation on the P&L statement.)
(MYL/ABT)—US Treasury’s new rules would appear to prohibit the “spinversion” deal between these companies in which MYL was to acquire ABT’s (negative-growth) branded-generics business in Europe, Japan, Canada, Australia, and New Zealand (#msg-104264092):
ABT -2% on fallout from ABBV-SHPG news (#msg-107202551). If MYL pulls out of its “spinversion” with ABT’s European branded-generics business (#msg-104271033), ABT will lose a great opportunity to unload its worst assets onto a company (MYL) who will buy just about anything to build “scale.”
ABT has (finally) sold all of its MYL shares acquired in the 2014 deal that allowed MYL to become a Dutch-domiciled corporation and allowed ABT to shed one of its worst businesses (#msg-104271033):